UroDX


Urologic Pathology Service Highlights:

• Comprehensive Test Menu
   o Histology and cytology services
   o Immunohistochemical and special stains are available to diagnose a wide range of neoplastic and infectious diseases.
   o Advanced Molecular Diagnostics
      • FISH
      • PCA3
      • Tumor markers

Prostate Histology

• All prostate biopsies are extensively studied with serial sections on multiple separate levels, resulting in 8-to-12 sections   examined on each biopsy core.
• Diagnostic report incorporating digital photography, diagrammatic representation of prostate gland, and color-coded   diagnoses.
• Immunohistochemical specialty stains, such as high-molecular weight cytokeratin, p63, and p504s (alpha-methylacyl-
  CoA racemase) for a definitive diagnosis in the evaluation of borderline lesions of minute foci of prostatic
  adenocarcinoma.
• In-house consultation by multiple board-certified pathologists with over 40 years of expertise in urologic pathology.
  View Sample Report | View Sample Report

Urine Cytology

• Routine Cytologic evaluation with collection kits provided.
• Detection and Monitoring of Recurrent Bladder Cancer
   • UroVysion™ FISH performed by specialists in FISH technology (In combination with routine cytology the multicolor       FISH probes provide the most sensitive and specific methodology for monitoring of recurrent bladder cancer.)
      View Sample Report
    

    For more information:

    UroVysionTM FISH Testing

    • UroVysionTM FISH Testing has been FDA approved as screen for recurrent bladder cancer, increasing the sensitivity       from 58% with routine cytology alone to 98% when used in combination with cytology and cystoscopy
    • This molecular test utilizes fluorescence in situ hybridization (FISH) to test abnormalities in four different       chromosomes linked to urothelial carcinomas. The use of FISH in conjuction with urine cytology can potentially
      reduce urothelial carcinoma morbidity and mortality by diagnosing these tumors earlier. UroVysionTM is not affected       by: BCG therapy, infections, BPH or hematuria.
    • This molecular test utilizes fluorescence in situ hybridization (FISH) to test abnormalities in four different       chromosomes linked to urothelial carcinomas. The use of FISH in conjunction with urine cytology can potentially       reduce urothelial carcinoma morbidity and mortality by diagnosing these tumors earlier. UroVysionTM is not affected       by: BCG therapy, infections, BPH or hematuria.
    • UroVysionTM and routine cytology can both be performed on the same specimen. Simply pour the urine into the       UroVysionTM Fish collection container and add an equal volume of the provided fixative. Order on the requisition       "CYTOLOGY & VROVYSION FISH". Then place the bar code label marked "UroVysion" on the container. The test       may be performed on voided urine or bladder washing specimens.
    • There is no need to send us two separate specimens. We will split the specimen for you.

• Stone analysis